UPDATED: Salix shares slide as analysts fret over Xifaxan IBS app; Dyax jerks EU app;

 @FierceBiotech: Special worms win over mice as Parkinson's drug tool. Article | Follow @FierceBiotech

 @JohnCFierce: There's no way to sugarcoat it. Geron's decision to abandon ESC work is a major setback for the field. Going to China?News | Follow @JohnCFierce

 @RyanMFierce: With Alex Denner leaving Icahn's group, does he resign from biotech boards he sits on through Icahn-backed campaigns? | Follow @RyanMFierce

 @MaureenFierce: FDA says Pfizer's best-selling Prevnar vaccine is comparable to Merck's vaccine. Story | Follow @MaureenFierce

> Shares of Salix Pharmaceuticals slid this morning as analysts digested some upsetting new questions the FDA wants to raise on its application for an approval to market Xifaxan for irritable bowel syndrome. An advisory committee is scheduled for tomorrow and Salix will be expected to defend the dosage it wants to have approved. Story

> NuPathe says it plans to resubmit its NDA for a transdermal migraine patch. NuPathe was handed a CRL on the application last August. Report

> Dyax says it will jerk its EU application for Kalbitor, a treatment for hereditary angioedema, citing a number of outstanding clinical issues that need to be resolved. Report

> Almirall and BioFocus will collaborate on the discovery of new compounds for key Almirall targets. Release

CORRECTION: A subhead in yesterday's FierceBiotech incorrectly stated that NuPathe jerked an EU application. Dyax jerked its application while NuPathe is planning a resubmission of an NDA application. We apologize for any confusion.

Pharma News

 @FiercePharma: Bloomberg's take on Multaq's failure in that permanent AF study: Sanofi med doubled risk of death pharma $SNY. News | Follow @FiercePharma

> In wake of Pallas study, Multaq hopes fade. Report

> Scorpion antivenom's price stings AZ patients. Article

Biotech Research News

> A possible way to stop a tumor from spreading: Look inside. Story

> Ziopharm goes organic for potential prostate cancer treatment. Report 

> Special worms win over mice as Parkinson's drug tool. Item

> Drug cuts off fat-tissue blood supply in monkeys and mice. Story

Manufacturing News

> IMS advises risk-based warning system for drug shortages. Item

> Booz offers 5 steps to reinvent supply chain. Report

> Five die in pharma plant fire. News

> FDA visits Indian plant after meningitis outbreak. Article

> Pfizer transforms manufacturing for 'dynamic market.' Story

> AMA counts to 10 before voting drug shortages position. News

And Finally... A mouse model designed to express a particular inflammatory enzyme was able to eat more without gaining weight by boosting its metabolism. Report

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.